Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06712355 | Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer | PHASE3 | RECRUITING | 621 | — | — | Feb 3, 2025 | Mar 1, 2029 | Jun 1, 2026 | 202 | United States, Australia +11 |
OS defined as the time from randomization to death from any cause.
| Arm | Type | Description |
|---|---|---|
| Stage 1 Control Arm - Atezolizumab + Etoposide + Carboplatin | ACTIVE_COMPARATOR | - |
| Stage 1 Treatment Arm 1 - Pumitamig Dose 1 + Etoposide + Carboplatin | EXPERIMENTAL | - |
| Stage 1 Treatment Arm 2 - Pumitamig Dose 2 + Etoposide + Carboplatin | EXPERIMENTAL | - |
| Stage 2 Control Arm - Atezolizumab + Etoposide + Carboplatin | ACTIVE_COMPARATOR | - |
| Stage 2 Treatment Arm - Pumitamig Dose 3 + Etoposide + Carboplatin | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Pumitamig | DRUG | Intravenous infusion |
| Atezolizumab | DRUG | Intravenous infusion |
| Etoposide | DRUG | Intravenous infusion and capsules |
| Carboplatin (or cisplatin if carboplatin is not tolerated) | DRUG | Intravenous infusion |
Inclusion Criteria: * Have histologically or cytologically confirmed ES-SCLC (using the AJCC \[American Joint Committee on Cancer\] tumor node metastasis staging system combined with Veterans Administration Lung Study Group \[VALG\]'s two stage classification scheme). For AJCC tumor node metastasis...